[go: up one dir, main page]

EP1292334A4 - Bispecific fusion protein and method of use for enhancing effector cell killing of target cells - Google Patents

Bispecific fusion protein and method of use for enhancing effector cell killing of target cells

Info

Publication number
EP1292334A4
EP1292334A4 EP01939954A EP01939954A EP1292334A4 EP 1292334 A4 EP1292334 A4 EP 1292334A4 EP 01939954 A EP01939954 A EP 01939954A EP 01939954 A EP01939954 A EP 01939954A EP 1292334 A4 EP1292334 A4 EP 1292334A4
Authority
EP
European Patent Office
Prior art keywords
fusion protein
target cells
effector cell
cell killing
bispecific fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01939954A
Other languages
German (de)
French (fr)
Other versions
EP1292334A1 (en
Inventor
Nabil Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of EP1292334A1 publication Critical patent/EP1292334A1/en
Publication of EP1292334A4 publication Critical patent/EP1292334A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01939954A 2000-06-22 2001-06-04 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells Withdrawn EP1292334A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21325200P 2000-06-22 2000-06-22
US213252P 2000-06-22
PCT/US2001/040835 WO2001097844A1 (en) 2000-06-22 2001-06-04 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells

Publications (2)

Publication Number Publication Date
EP1292334A1 EP1292334A1 (en) 2003-03-19
EP1292334A4 true EP1292334A4 (en) 2003-11-19

Family

ID=22794334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939954A Withdrawn EP1292334A4 (en) 2000-06-22 2001-06-04 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells

Country Status (5)

Country Link
EP (1) EP1292334A4 (en)
JP (1) JP2003535908A (en)
AU (2) AU6541801A (en)
CA (1) CA2412901A1 (en)
WO (1) WO2001097844A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (en) * 2016-03-17 2016-11-02 中国药科大学 The preparation of a kind of cytokine fusion antibody and application thereof

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
KR101289537B1 (en) * 2005-02-15 2013-07-31 듀크 유니버시티 Anti-cd19 antibodies and uses in oncology
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
EP2200634B1 (en) * 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
JP5699362B2 (en) * 2008-04-10 2015-04-08 アイビーシー ファーマスーティカルズ,インコーポレイテッド Modular method for preparing tetrameric cytokines with improved pharmacokinetics by dock-and-lock (DNL) technology
WO2011053322A1 (en) * 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
EA034989B1 (en) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Polypeptide construct for use in treating cancer comprising attenuated alpha interferon
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CA2909952C (en) * 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
MA42136A (en) 2015-05-20 2018-03-28 Janssen Biotech Inc ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38 POSITIVE HEMATOLOGICAL MALIGNANT TUMORS
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MX2018005315A (en) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER.
AU2016343805A1 (en) 2015-10-30 2018-06-07 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN109195634A (en) * 2016-04-15 2019-01-11 延龄草疗法有限公司 Macrophage-stimulating in CD47 blocking treatment
JP7241677B2 (en) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-CD47 combination therapy
WO2019023156A1 (en) * 2017-07-24 2019-01-31 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
JP6648171B2 (en) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Fusion with anti-CD38 antibody and attenuated interferon alpha-2B
EP3759144A1 (en) * 2018-03-01 2021-01-06 Glycotope GmbH Fusion protein constructs comprising an anti-muc1 antibody and il-15
CN119264273A (en) 2019-12-03 2025-01-07 埃沃特克国际有限责任公司 Interferon-related antigen binding protein and its use
JP6853392B2 (en) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Fusion with anti-CD38 antibody and attenuated interferon alfa-2B

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
OZZELLO L ET AL: "CONJUGATION OF INTERFERON ALPHA TO A HUMANIZED MONOCLONAL ANTIBODY (HUBRE-3VL) ENHANCES THE SELECTIVE LOCALIZATION AND ANTITUMOR EFFECTS OF INTERFERON IN BREAST CANCER XENOGRAFTS", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 48, no. 2, 1998, pages 135 - 147, XP000940608, ISSN: 0167-6806 *
OZZELLO L ET AL: "EXPERIMENTAL IMMUNOTHERAPY OF BREAST CANCER USING ALPHA INTERFERON CONJUGATED TO MONOCLONAL ANTIBODY MC5", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 353, 1994, pages 35 - 46, XP000940596, ISSN: 0065-2598 *
PALLELA V R ET AL: "INTERFERON-ALPHA-2B IMMUNOCONJUGATE FOR IMPROVING IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 41, no. 6, June 2000 (2000-06-01), pages 1108 - 1113, XP000940586, ISSN: 0161-5505 *
See also references of WO0197844A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (en) * 2016-03-17 2016-11-02 中国药科大学 The preparation of a kind of cytokine fusion antibody and application thereof

Also Published As

Publication number Publication date
JP2003535908A (en) 2003-12-02
AU2001265418B2 (en) 2006-03-30
AU6541801A (en) 2002-01-02
EP1292334A1 (en) 2003-03-19
WO2001097844A1 (en) 2001-12-27
CA2412901A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU6541801A (en) Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
IL153906A0 (en) Method for direct genetic analysis of target cells
IL208510A0 (en) Method of collecting placental stem cells
IL207008A (en) Decellularized or synthetic tissue-s matrices comprising human placental stem cells and methods for preparation thereof
IL149802A0 (en) Method of cryopreserving selected sperm cells
GB2390221B (en) Ion beam charge neutralizer and method therefor
AU3064799A (en) Ion mobility storage trap and method
AU2002360540A1 (en) Method for intracellular modifications within living cells using pulsed electric fields
AU2003210884A8 (en) Preparations of nucleus pulposus cells and methods for their generation, identification, and use
AU2786100A (en) Method of selecting transformed cells and tissues
AU9109001A (en) Method for use of IGF-binding protein for selective sensitization of target cells in vivo
EP1368029A4 (en) Method and composition for rejuvinating cells, tissues, organs, hair and nails
AU2002309989A1 (en) Directed evolution of protein in mammalian cells
AU1417701A (en) Soluble t cell receptor protein and method of constructing the same
AU8848998A (en) Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2003264075A8 (en) Active fusion proteins and method for the production thereof
AU2003229484A1 (en) Device and method for cultivating tissue cells
AU2001236064A1 (en) Method for analysis of substances in tissue or in cells
AU2002333706A1 (en) Method and means for modulating plant cell cycle proteins and their use in plant cell growth control
HUP0102697A3 (en) Method of making proteins in transformed yeast cells
HK1069115A (en) Method for use of igf-binding protein for selective sensitization of target cells in vivo
GB2370039B (en) Producing protein arrays and fusion protein for use therein
AU2354501A (en) A new method for the examination of protein localization in living cells
AU1226301A (en) Stem cell engraftment-enhancing cellular proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 19/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20031002

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

17Q First examination report despatched

Effective date: 20050228

17Q First examination report despatched

Effective date: 20050228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090723